FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3048830971> ?p ?o ?g. }

• W3048830971 abstract "CFTR modulators decrease some etiologies of CF airway inflammation; however, data indicate that non-resolving airway infection and inflammation persist in individuals with CF and chronic bacterial infections. Thus, identification of therapies that diminish airway inflammation without allowing unrestrained bacterial growth remains a critical research goal. Novel strategies for combatting deleterious airway inflammation in the CFTR modulator era require better understanding of cellular contributions to chronic CF airway disease, and how inflammatory cells change after initiation of CFTR modulator therapy. Peripheral blood monocytes, which traffic to the CF airway, can develop both pro-inflammatory and inflammation-resolving phenotypes, represent intriguing cellular targets for focused therapies. This therapeutic approach, however, requires a more detailed knowledge of CF monocyte cellular programming and phenotypes.In order to characterize the inflammatory phenotype of CF monocytes, and how these cells change after initiation of CFTR modulator therapy, we studied adults (n=10) with CF, chronic airway infections, and the CFTR-R117H mutations before and 7 days after initiation of ivacaftor. Transcriptomes of freshly isolated blood monocytes were interrogated by RNA-sequencing (RNA-seq) followed by pathway-based analyses. Plasma concentrations of cytokines and chemokines were evaluated by multiplex ELISA.RNAseq identified approximately 50 monocyte genes for which basal expression was significantly changed in all 10 subjects after 7 days of ivacaftor. Of these, the majority were increased in expression post ivacaftor, including many genes traditionally associated with enhanced inflammation and immune responses. Pathway analyses confirmed that transcriptional programs were overwhelmingly up-regulated in monocytes after 7 days of ivacaftor, including biological modules associated with immunity, cell cycle, oxidative phosphorylation, and the unfolded protein response. Ivacaftor increased plasma concentrations of CXCL2, a neutrophil chemokine secreted by monocytes and macrophages, and CCL2, a monocyte chemokine.Our results demonstrate that ivacaftor causes acute changes in blood monocyte transcriptional profiles and plasma chemokines, and suggest that increased monocyte inflammatory signals and changes in myeloid cell trafficking may contribute to changes in airway inflammation in people taking CFTR modulators. To our knowledge, this is the first report investigating the transcriptomic response of circulating blood monocytes in CF subjects treated with a CFTR modulator." @default.
• W3048830971 created "2020-08-18" @default.
• W3048830971 creator A5005871186 @default.
• W3048830971 creator A5021250855 @default.
• W3048830971 creator A5034081739 @default.
• W3048830971 creator A5041260850 @default.
• W3048830971 creator A5042815840 @default.
• W3048830971 creator A5046112250 @default.
• W3048830971 creator A5046388349 @default.
• W3048830971 creator A5052909330 @default.
• W3048830971 creator A5060144400 @default.
• W3048830971 creator A5061871604 @default.
• W3048830971 creator A5068050504 @default.
• W3048830971 date "2020-08-13" @default.
• W3048830971 modified "2023-09-30" @default.
• W3048830971 title "CFTR Modulator Therapy Enhances Peripheral Blood Monocyte Contributions to Immune Responses in People With Cystic Fibrosis" @default.
• W3048830971 cites W1644749979 @default.
• W3048830971 cites W1777296950 @default.
• W3048830971 cites W1843040414 @default.
• W3048830971 cites W1971512067 @default.
• W3048830971 cites W1971924555 @default.
• W3048830971 cites W1975572445 @default.
• W3048830971 cites W1987169606 @default.
• W3048830971 cites W1998419755 @default.
• W3048830971 cites W1999958668 @default.
• W3048830971 cites W2032069970 @default.
• W3048830971 cites W2049463810 @default.
• W3048830971 cites W2051836609 @default.
• W3048830971 cites W2064206684 @default.
• W3048830971 cites W2071266503 @default.
• W3048830971 cites W2078078890 @default.
• W3048830971 cites W2078357058 @default.
• W3048830971 cites W2079107579 @default.
• W3048830971 cites W2087401044 @default.
• W3048830971 cites W2092177169 @default.
• W3048830971 cites W2093327053 @default.
• W3048830971 cites W2096694356 @default.
• W3048830971 cites W2101012696 @default.
• W3048830971 cites W2104893458 @default.
• W3048830971 cites W2111797194 @default.
• W3048830971 cites W2116926077 @default.
• W3048830971 cites W2124135806 @default.
• W3048830971 cites W2128583360 @default.
• W3048830971 cites W2130410032 @default.
• W3048830971 cites W2131816101 @default.
• W3048830971 cites W2133497705 @default.
• W3048830971 cites W2134526812 @default.
• W3048830971 cites W2137082708 @default.
• W3048830971 cites W2137531873 @default.
• W3048830971 cites W2140868856 @default.
• W3048830971 cites W2144131446 @default.
• W3048830971 cites W2153307836 @default.
• W3048830971 cites W2157600239 @default.
• W3048830971 cites W2158544918 @default.
• W3048830971 cites W2163932712 @default.
• W3048830971 cites W2164805416 @default.
• W3048830971 cites W2169456326 @default.
• W3048830971 cites W2179438025 @default.
• W3048830971 cites W2207982651 @default.
• W3048830971 cites W2255823216 @default.
• W3048830971 cites W2301044272 @default.
• W3048830971 cites W2301131921 @default.
• W3048830971 cites W2316096704 @default.
• W3048830971 cites W2400611618 @default.
• W3048830971 cites W2466058746 @default.
• W3048830971 cites W2586398817 @default.
• W3048830971 cites W2589471515 @default.
• W3048830971 cites W2589766919 @default.
• W3048830971 cites W2742088396 @default.
• W3048830971 cites W2752923425 @default.
• W3048830971 cites W2763628584 @default.
• W3048830971 cites W2766377163 @default.
• W3048830971 cites W2770939160 @default.
• W3048830971 cites W2784278501 @default.
• W3048830971 cites W2887119856 @default.
• W3048830971 cites W2900569176 @default.
• W3048830971 cites W2900581749 @default.
• W3048830971 cites W2913858653 @default.
• W3048830971 cites W2914165966 @default.
• W3048830971 cites W2921486742 @default.
• W3048830971 cites W2927955189 @default.
• W3048830971 cites W2936485366 @default.
• W3048830971 cites W2946173685 @default.
• W3048830971 cites W2946851315 @default.
• W3048830971 cites W2950985821 @default.
• W3048830971 cites W2963861915 @default.
• W3048830971 cites W2967035454 @default.
• W3048830971 cites W2970919782 @default.
• W3048830971 cites W2979464486 @default.
• W3048830971 cites W2993867855 @default.
• W3048830971 cites W2995039198 @default.
• W3048830971 cites W3017148788 @default.
• W3048830971 cites W4210975044 @default.
• W3048830971 cites W4232966707 @default.
• W3048830971 cites W4246782132 @default.
• W3048830971 doi "https://doi.org/10.3389/fphar.2020.01219" @default.
• W3048830971 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7461946" @default.
• W3048830971 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33013356" @default.
• W3048830971 hasPublicationYear "2020" @default.
• W3048830971 type Work @default.

• next